The Effects of Replacing Dihydropyridine Calcium-channel Blockers with Angiotensin II Receptor Blocker on the Quality of Life of Hypertensive Patients

Blood Pressure, Supplement

Volumn 12, Issue 2, 2003, Pages 22-28

  Yamamoto, Shigeki ^a   Kawashima, Takashi ^a   Kunitake, Toshiaki ^a   Koide, Shinichiro ^a   Fujimoto, Hiroshi ^a  

^a Mitsubishikagaku Hospital   (Japan)

Author keywords

Angiotensin II receptor blocker; Calcium antagonist; Hypertension; Quality of life

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ARANIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CILNIDIPINE; DIHYDROPYRIDINE DERIVATIVE; EFONIDIPINE; FELODIPINE; MANIDIPINE; MEPIRODIPINE; NIFEDIPINE; NILVADIPINE; NISOLDIPINE; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CALCIUM CHANNEL L TYPE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; FLUSHING; HEART PALPITATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NOCTURIA; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEXUAL FUNCTION; SIDE EFFECT; SLEEP PARAMETERS; TREATMENT OUTCOME; WELLBEING; WORK; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG SCREENING; FOLLOW UP; HEART RATE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 80052610439     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: 10.1080/08038020310016378     Document Type: Article

References (20)

1. Fowl M, Berkeley J. Quality of life - a review of the literature. Family Pract 1987; 4: 226-34.
2. Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med 1992; 116: 166-7.
3. Beto JA, Bansal VK. Quality of life in treatment of hypertension: a metaanalysis of clinical trails. J Hypertens 1992; 5: 125-33.
4. Kozma A, Stones MJ. The measurement of happiness: Development of the Memorial University of Newfoundland Scale of happiness (MUNSH). J Gerontol 1980; 35: 906-12.
5. Viet CT, Ware JE. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 1983; 14: 74-81.
6. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown CR. Optimization of antihypertensive treatment by cross-over rotation of four major classes. Lancet 1999: 353: 2008-13.
7. Fletcher AE, Bulpitt CJ, Hawkins CM, et al. Quality of life on antihypertensive therapy: a randomized double blind controlled trail of captopril and atenolol. J Hypertens 1990; 8: 463-6.
8. Heuer HJ, Schondorfer G, Hogemann AM. Twenty-four-hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 Suppl 2: S55-6.
9. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonists, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 Suppl 2: S49-53.
10. Ogiwara T, Nakagawa M, Ishikawa H, et al. Effect of manidipine, a novel calcium channel blocker, on quality of life in hypertensive patients. Blood Press 1992; 3 Suppl: 135-9.
11. Buert VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Hypertension 1995; 25: 305.
12. Jachuck SJ, Brierley H, Jachuck S, Willcox PM. The effect of hypotensive drugs on the quality life. J R Coll Gen Pract 1982; 32: 103-95.
13. Henning M. Pharmacology of antihypertensive drugs in Amsterdam. In: Hardbook of hypertension, Vol. 3. Van Zwiten PA, Ed. Elsevier, 1984.
14. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-13.
15. Lacourciere Y, Asmar R. A comparison of efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertension 1999; 12: 1181-7.
16. Himmelmann A, Keinanen-kiukaanniemi S, Wester A, Redon J, Asmar R, Hendner T. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press 2001; 10: 43-51.
17. Farsang C, Kawecka-Jaszcz K, Langan J, Maritz F, Zannad F. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001; 21: 17-23.
18. Schutle K-L, Fischer M, Lenz T, Meyer-Sabellek W. Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs. Clin Drug Invest 1999; 18: 453-60.
19. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. The quality-of-life hypertension study group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. N Eng J Med 1993; 328: 907-13.
20. Sun YP, Zhu BQ, Browne AE, et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 2001; 6: 175-81.